|Bid||2.830 x 2200|
|Ask||2.840 x 1200|
|Day's Range||2.800 - 3.000|
|52 Week Range||1.020 - 27.976|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 6, 2017 - Nov 10, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||12.14|
Axovant Sciences (AXON) today announced that Pavan Cheruvu, M.D., chief executive officer, will present a corporate overview at the first annual Roivant Pipeline Day on July 10, 2018 at 4:30 p.m. ET. A live webcast will be available in the Investors section of Axovant's website at www.axovant.com. Roivant Pipeline Day will be held on Tuesday, July 10, 2018 in New York City.
Axovant Sciences (AXON) and Oxford Biomedical aim to develop AXO-Lenti-PD gene therapy as a long-term treatment for PD (Parkinson’s disease). Once administered using MRI1-guided stereotactic delivery, this gene therapy could help reduce motor fluctuations resulting from depleting dopamine levels in the brain.
Between March 31 and June 8, Axovant Sciences (AXON) stock rose ~284% from $1.69 to $4.80, largely due to the company’s entry into lentiviral vector gene therapy for PD (Parkinson’s disease) through a licensing arrangement with Oxford BioMedica. Axovant Sciences has secured worldwide development and commercialization rights for its investigational therapy, AXO-Lenti-PD, which aims to restore dopamine in the striatum of PD patients’ brain.
Axovant Sciences (AXON) stock rose 150% in the week of June 1–8. Over the last quarter, Axovant Sciences stock has risen 192.7%. On June 6, Axovant Sciences entered into a licensing agreement for worldwide rights to develop and sell Oxford BioMedica’s OXB-102 investigational gene therapy for the treatment of Parkinson’s disease.
As a micro-cap company, Axovant Sciences Ltd (NASDAQ:AXON) is naturally fraught with risks. The company is losing money and debt levels are elevated at 0.49 times equity. AXO-Lenti-PD is a gene therapy for treating Parkinson’s disease.
Axovant Sciences Ltd’s (NASDAQ:AXON): Axovant Sciences Ltd., a clinical-stage biopharmaceutical company, engages in developing and commercializing medicines for the treatment of dementia and related neurological disorders in the United StatesRead More...
After an organizational restructuring that followed the announcement of negative Phase 3 trial results for a drug being developed as a therapy for Alzheimer’s disease, Roivant spinoff Axovant has inked an $842 million gene therapy deal expected to boost development out of Durham.
LONDON, UK / ACCESSWIRE / June 08, 2018 / If you want access to our free research report on Axovant Sciences Ltd (NASDAQ: AXON) ("Axovant"), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=AXON as the Company's latest news hit the wire. On June 06, 2018, the Company announced that it has signed an exclusive worldwide licensing deal with Oxford BioMedica to develop and commercialize OXB-102 (now AXO-Lenti-PD), a gene therapy developed by Oxford BioMedica for Parkinson's disease utilizing the LentiVector® platform. Active-Investors.com is currently working on the research report for ProQR Therapeutics N.V. (NASDAQ: PRQR), which also belongs to the Healthcare sector as the Company Axovant Sciences.
Axovant Sciences' (AXON) shares rally, following news of a licensing deal for AXO-LentiPD from Oxford BioMedica for Parkinson's disease.
Axovant Sciences Ltd (NASDAQ: AXON ) announced Wednesday that it licensed global rights to Oxford BioMedica’s investigational gene therapy for Parkinson’s Disease. As some experts see it, the drug could ...
For three straight sessions, the tech-heavy index has set record closing highs even as its fellow major stock indexes have moved in and out of the green. While Nasdaq's record streak was in jeopardy early Thursday, June 7, these stocks have been leading the index's push higher. shares have risen 5.75% over the past five sessions.
Axovant Sciences (AXON) is a clinical-stage biopharmaceutical company. The company’s stock price jumped ~160.0% to the closing price of $4.55 on June 6 due to several factors. Axovant Sciences stock price has increased by ~137.0% in the last three trading sessions.
NEW YORK, NY / ACCESSWIRE / June 7, 2018 / Axovant Sciences was one of the biggest gainers in the stock market on Wednesday after announcing that it has licensed an investigational gene therapy for Parkinson's Disease from Oxford BioMedica. Shares of Heat Biologics also climbed a lot higher despite any news. The company's CEO was said to present at the 2018 BIO International Convention on Wednesday.
Cell and gene therapy development hitting fever pitch globally as more products enter phase 3 and late-stage testing. Growing their sales consistently, and partnered with high-profile public clients, ORGS could be significantly undervalued with continued executiona and expansion. NEW YORK, NY / ACCESSWIRE / June 7, 2018 / The curative potential of gene and cell therapies has kept these new pharmaceutical products front and center for healthcare investors for the last 3 years.
Axovant Sciences Ltd. investors are enjoying their first rays of light in months as the shares more than doubled on the company’s plan to license a gene therapy from Oxford BioMedica Plc. Axovant agreed to pay the U.K.-listed company $30 million upfront in cash for rights to develop OXB-102 for Parkinson’s disease. Oxford could get an additional $812.5 million if certain development and sales milestones are reached.